CervoMed Inc. Files 8-K

Ticker: CRVO · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1053691

Cervomed Inc. 8-K Filing Summary
FieldDetail
CompanyCervomed Inc. (CRVO)
Form Type8-K
Filed DateJan 31, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financial-reporting

TL;DR

CervoMed Inc. filed an 8-K on Jan 31, 2025. Important for investors.

AI Summary

CervoMed Inc. filed an 8-K on January 31, 2025, reporting on other events and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing provides an update on CervoMed Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events or financial updates without immediate market-moving news.

Key Numbers

  • 001-37942 — Commission File Number (Identifies the company's SEC filing history)
  • 30-0645032 — I.R.S. Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • CervoMed Inc. (company) — Registrant
  • Diffusion Pharmaceuticals Inc. (company) — Former company name
  • RestorGenex Corp (company) — Former company name
  • Stratus Media Group, Inc (company) — Former company name
  • January 31, 2025 (date) — Date of report
  • Boston, Massachusetts (location) — Company headquarters

FAQ

What is the primary purpose of this 8-K filing for CervoMed Inc.?

The 8-K filing serves as a current report for CervoMed Inc., covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits as of January 31, 2025.

When was CervoMed Inc. incorporated and where is it headquartered?

CervoMed Inc. is incorporated in Delaware and its business address is located at 20 Park Plaza, Suite 424, Boston, Massachusetts, 02116.

What were some of CervoMed Inc.'s former company names?

CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc.

What is CervoMed Inc.'s standard industrial classification?

CervoMed Inc.'s Standard Industrial Classification is Pharmaceutical Preparations [2834].

What is the SEC file number for CervoMed Inc.?

The SEC file number for CervoMed Inc. is 001-37942.

Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-01-31 08:18:31

Key Financial Figures

  • $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

01

Item 7.01 Regulation FD Disclosure Press Release On January 31, 2025, CervoMed Inc. (the "Company") issued a press release providing an update on its neflamapimod development program in dementia with Lewy bodies in connection with the Company's oral presentation at the 8 th International Lewy Body Dementia Conference (ILDBC). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Presentation Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company is being made available on its website, www.cervomed.com, under the heading, "Investors – Events and Presentations" and a copy of which is attached as Exhibit 99.2 hereto. Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others, including a presentation of the information contained therein at the ILDBC on January 31, 2025. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission ("SEC") and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in

01

Item 8.01 Other Events The information set forth in the first and second paragraphs of the Company's press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits The following exhibits relating to Item 7.01 are furnished and not filed: Exhibit No. Description 99.1 Press Release, issued January 31, 2025. 99.2 Presentation of CervoMed Inc., dated January 31, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 31, 2025 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.